Clinical Evaluation of the GeneXpert[®] Xpert[®] Xpress SARS CoV-2/Flu/RSV *PLUS* Combination Test

Grant Johnson^{1,2}, Branden S.J. Gregorchuk³, Arek Zubrzycki¹, Kurt Kolsun^{3,4}, Adrienne F.A. Meyers^{3,5}, Paul A. Sandstrom^{3,5}, Michael G. Becker^{3,4,*}

- ¹ Laboratory Medicine and Infection Prevention and Control, Lakeridge Health, Oshawa, Ontario, Canada.
- 6 ² Ontario Tech University, Oshawa, Ontario, Canada.
- ³ National HIV and Retrovirology Laboratories, National Microbiology Laboratory Branch, JC Wilt Infectious
 Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada
- 9 ⁴ Department of Microbiology, University of Manitoba, Winnipeg, Canada
- 10 ⁵ Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
- 12 * Correspondence: <u>michael.glen.becker@phac-aspc.gc.ca</u>
- 13

14 Abstract

15 The GeneXpert[®] Xpert[®] Xpress SARS-CoV-2/Flu/RSV *PLUS* combination test (*PLUS* Assay)

- 16 received Health Canada approval in January 2022. The PLUS Assay is similar to the SARS-CoV-
- 17 2/Flu/RSV combination test, with modifications to improve assay robustness against circulating
- 18 and emerging variants. The performance characteristics of the *PLUS* Assay were assessed at the
- 19 Lakeridge Health Oshawa Hospital Centre and the National Microbiology Laboratory of
- 20 Canada. The PLUS Assay was directly compared to the SARS-CoV-2/Flu/RSV combination test
- 21 using SARS-CoV-2 culture from five variants and remnant clinical specimens collected across
- the COVID-19 pandemic. This included 50 clinical specimens negative for all pathogens, 110
- 23 clinical specimens positive for SARS-CoV-2, Influenza A, Influenza B, RSVA, and/or RSVB and
- 24 an additional 11 mixed samples to screen for target interactions. The *PLUS* Assay showed a
- 25 high percent agreement with the widely used SARS-CoV-2/Flu/RSV combination test. Based on
- 26 these findings, the PLUS Assay and the Xpert SARS-CoV-2/Flu/RSV combination test results are
- 27 largely consistent with no observed difference in sensitivity, specificity, or time to result when
- challenged with various SARS-CoV-2 variants. The reported Ct values provided by the new
- 29 PLUS Assay was also unchanged, with the exception of a possible 1-2 decrease reported Ct for
- 30 RSVA across a limited sample size.

31 Introduction

The coronavirus disease 2019 (COVID-19) pandemic has lead to an enormous demand 32 33 for diagnostic testing. To this end, numerous antigen and molecular SARS-CoV-2 rapid tests 34 have been approved by the United States Food and Drug Administration and Health Canada, 35 including the Cepheid GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV Combination Test. 36 The GeneXpert and its associated COVID-19 cartridges perform a rapid, fully-automated, and 37 self-contained multiplex RT-qPCR tests with run times of 45 minutes or less (Cepheid Package 38 Insert, 2021). The Xpert SARS-CoV-2/Flu/RSV assay targets two SARS-CoV-2 genomic regions, 39 the envelope (E) and the nucleocapsid (N2) returning a cycle threshold (Ct) value if the target is 40 detected as well as its qualitative result interpretation within 45 amplification cycles. The results 41 for the SARS-CoV-2/Flu/RSV combination test reports the fluorescence values for both the E and 42 N2 targets of SARS-CoV-2 as a single result as they occupy the same fluorescence channel 43 (Johnson et al., 2021). Additionally, the Xpert SARS-CoV-2/Flu/RSV combination test is able to 44 detect influenza A, influenza B as well as respiratory syncytial virus (RSV), and will report their 45 respective Ct values.

As SARS-CoV-2 variants of concern continue to emerge worldwide, Cepheid developed 46 47 a new formulation of their Xpert SARS-CoV-2/Flu/RSV combination test, the Xpert SARS-CoV-48 2/Flu/RSV PLUS combination test (referred to hereafter as the PLUS Combination Test). The 49 PLUS Combination Test has an additional SARS-CoV-2 target, RNA-Dependent RNA 50 Polymerase (RdRp), to help improve assay robustness against novel SARS-CoV-2 variants and 51 redesigned N2 oligos for better coverage of nucleocapsid mutations in circulation that have 52 been shown to cause N gene detection dropout using GeneXpert SARS-CoV-2 assays (Foster et 53 al., 2022; Isabel et al., 2022). RdRp (also known as nsp-12) is the catalytic subunit of multi-54 subunit polymerase complex which, along with nsp-7 and nsp-8, forms the minimal core 55 components for SARS-CoV-2 RNA synthesis (Peng et al., 2020). To date, there has been no 56 identified RdRp modifications, with this region being considered relatively stable target due to 57 its conserved function (te Velthuis et al., 2009; Pachetti et al., 2020; Peng et al., 2020). RdRp is

measured on the same fluorescence channel as targets E and N2, and thus a single Ct value isreported for SARS-CoV-2.

60 As a rapid near-point-of-care device, the GeneXpert system is currently used as a testing 61 option to improve turnaround times in major health centres, and is used heavily in critical care settings (Jokela et al., 2020; Gotham et al., 2021). Additionally, the GeneXpert has been a reliable 62 63 tool for decentralized testing in remote and isolated Canadian communities (Respiratory Virus 64 Infections Working Group, 2020) where access to large, well-equipped laboratories is not 65 possible (Berry et al., 2020; Jokela et al., 2020; Gotham et al., 2021; Yau et al., 2021; Rong et al., 66 2022). It has also been used internationally by the World Health Organization in developing 67 countries during their response to the COVID-19 pandemic (Rakotosamimanana et al., 2020; 68 World Health Organization, 2020).

The individual Xpert Xpress SARS-CoV-2 and Xpert Xpress Flu/RSV assays have 69 70 demonstrated high sensitivity in numerous analytical and clinical studies with company 71 reported sensitivity of 100% (n=35) at 250 copies (cp)/mL for its SARS-CoV-2 assay; independent 72 studies have reported a limit of detection (LOD) ranging from 8.3 – 60 cp/mL (3–4). Indeed, the 73 assay has shown excellent agreement with the Roche Cobas 6800 system (Broder et al., 2020; 74 Goldenberger et al., 2020; Lieberman et al., 2020; Moran et al., 2020; Smithgall et al., 2020; Tham et 75 al., 2021), the Hologic Panther Fusion (Hogan et al., 2020), as well as laboratory-developed RT-76 qPCR tests (Lieberman et al., 2020; Wolters et al., 2020). A recent systematic review of the Xpert 77 Xpress assay indicated an overall specificity and sensitivity of 97% based on a selection of 11 78 studies (Goldenberger *et al.*, 2020). As the GeneXpert is present a plethora of settings (including 79 clinics, hospitals, health centres, nursing stations), an independent evaluation of the recently approved PLUS Combination Test ahead of the approaching flu season is essential. 80

In our study, remnant clinical samples of SARS-CoV-2, influenza A (H3 and H1 2009), influenza B, RSVA, and RSVB were used to evaluate the *PLUS* Combination Test and compare it to the SARS-CoV-2/Flu/RSV Combination Test (Johnson *et al.*, 2022). This evaluation was performed in two independent laboratories, the National Microbiology Laboratory (NML; Winnipeg, Canada) and Lakeridge Health Oshawa Hospital (Oshawa, Canada). The SARS-CoV-

2 samples used in this study were collected across multiple waves of the pandemic, and included SARS-CoV-2 Alpha, Delta, Omicron BA.1, and Omicron BA.2 variants. Additionally, inactivated SARS-CoV-2 culture from five variants was tested on both assays. No difference was observed between the assays concerning sensitivity, reported Ct value, run time, or specificity.

90 Materials and Methods

91 <u>Clinical Specimens</u>

92 Remnant universal transport media (UTM) from nasopharyngeal or nasal clinical swabs 93 collected at the Cadham Provincial Laboratory (Winnipeg, Canada), Lakeridge Health Oshawa 94 Hospital (Oshawa, Canada), and the Public Health Ontario Laboratory (Toronto, Canada) were 95 used. Study samples included 50 clinical specimens negative for SARS-CoV-2, Influenza A, 96 Influenza B, and RSV, with an additional 99 clinical positive specimens containing any one or 97 more of the following pathogens: SARS-CoV-2, Influenza A, Influenza B, or RSV. Fifty-nine of 98 the study samples (50 negatives, 7 COVID-19 positive, 2 Influenza positive) were obtained from 99 prospective sampling of patients presenting with COVID-19 symptoms. The remainder of the 100 study samples were previously characterized by laboratory-developed RT-qPCR tests (i.e. the 101 ResPlex Assay or the Cepheid GeneXpert with the SARS-CoV-2/Flu/RSV Combination Test; 102 Supplemental Data 1). Selected samples were stratified to cover a wide range of Ct values, from 103 approximately 15-40. All samples tested at the National Microbiology Laboratory of Canada 104 each RSV sample were typed as RSVA or RSVB, which is indicated in Supplemental Data 1. In 105 total, this study included 7 RSVA samples, 9 RSVB samples, and 10 RSV samples that were not 106 typed.

107 To simulate patient coinfection with multiple viruses, remnant transport media from an 108 additional 26 clinical specimens were mixed in various combinations to create 11 contrived 109 samples, each containing two or three different respiratory viral pathogens, and tested using 110 both Xpert assays (Supplemental Data 1). All samples used in this study were research ethics 111 board-exempt, anonymized, diagnostic samples used for assay validation. To determine overall

112	test agreement, 300	μL of transport	media from	nasal or	nasopharyngeal	swabs was	tested in

113 parallel with the SARS-CoV-2/Flu/RSV combination test and the *PLUS* Combination Test. .

114

115 <u>Gamma-irradiated SARS-CoV-2 culture</u>

116 High-titre inactivated SARS-CoV-2 culture of the Alpha (B.1.1.7), Delta (B.1.617.2), Omicron BA.1 (BA.1), Omicron BA.2 (BA.2), and wild type (WA-1) variants was provided by 117 118 the Special Pathogens Program of the National Microbiology Laboratory Branch (NMLB; 119 Winnipeg, MB). SARS-CoV-2 variants were propagated in Vero cells in Minimal Essential 120 Medium and clarified by low speed centrifugation. The viral supernatant was inactivated via 121 gamma-irradiation using a Gammacell 220 Cobalt-60 irradiator with a total exposure of three 122 Mrad of radiation. The reported stock concentrations of the viral variant preparations were 123 2.1x106 PFU/mL (Alpha), 2.3x105 PFU/mL (Delta), 2.1x105 PFU/mL (Omicron BA1), 1.9x105 124 PFU/mL (Omicron BA.2), and 1.2x10⁶ PFU/mL (wild type). Inactivated culture fluid was serially 125 diluted in UTM and Ct values were determined using the GeneXpert® Xpert® Xpress SARS-126 CoV-2 assay. Dilutions were performed to obtain Ct values of approximately 33 and 36, 127 approaching the limit of detection of the GeneXpert assay. Ct values were converted into cp/mL using a standard curve (Becker et al., 2020). Characterization of dilutions are summarized in 128 129 Table 1. 300 µL of the diluted culture fluid was tested in duplicate using both the SARS-CoV-130 2/Flu/RSV combination test and the PLUS Combination Test.

131

132 Results

Inactivated gamma-irradiated SARS-CoV-2 culture of five isolates (Wild-Type (WA-1), Alpha (B.1.1.7), Delta (B.1.617.2), Omicron (BA.1), and Omicron (BA.2)) were used to investigate the performance of the *PLUS* Combination Test against current or previous circulating variants. A panel of five cultured SARS-CoV-2 isolates was tested with the SARS-CoV-2/Flu/RSV combination test and the *PLUS* Combination Test (Table 1). All variants were detected with both assays at all dilutions and replicates. Additionally, SARS-CoV-2 positive and SARS-CoV-2 negative clinical samples were tested with both the *PLUS* Combination Test and SARS-CoV-2

2/Flu/RSV combination test (Table 2). The Ct values of SARS-CoV-2 positive samples ranged from 15.6 to 43.5 (Fig. 1; Supplemental Data 1). There was 100% agreement between both assays, with 57 positives and 103 negatives detected (Table 2). There was a high level of correlation between the SARS-CoV-2 Ct values reported with both of the assays (Figure 1; $R^2 = 0.973$), with an average standard deviation of 0.49 Ct values between the reported results (Supplemental Data 1).

146 The above process was repeated for clinical samples containing Influenza A, Influenza B, 147 and RSV. Similarly, results were highly consistent between the PLUS Combination Test and 148 SARS-CoV-2/Influenza/RSV combination test, with overall percent agreements of 100%, 99.4%, 149 and 100% for influenza A, influenza B, and RSV, respectively (Table 3). Regardless of RSV 150 subtype, all RSV positive clinical samples were detected using both assays (Table 3; 151 Supplemental Data 1). Likewise, high correlations were observed between the Ct values 152 reported by both Xpert assays for influenza A (Figure 1; $R^2 = 0.978$), influenza B ($R^2 = 0.984$), and 153 RSV ($R^2 = 0.975$). The correlation for RSV targets was maintained when broken down further by 154 subtype (Supplemental Figure 1). Variance between the Ct values reported by each assay was 155 also low for all targets, with an average Ct value standard deviation of 0.22 for influenza A, 0.24 156 for influenza B, and 0.36 for RSV (Supplemental Data 1). When RSV was analyzed by subtype, 157 average Ct value standard deviation was greatest for RSVA at 0.72 (n=7), with measured Ct 158 values an average of 1.4 cycles lower with the PLUS Combination Test (Supplemental Figure 1; 159 Supplemental Data 1). The average run time from insertion of the cartridge to its ejection was 160 timed for both the PLUS Combination Test and SARS-CoV-2/Flu/RSV Combination Test. There 161 was no difference in run time between the two assays, with an average of 36.5 minutes to assay 162 completion (Supplemental Data 1).

163 Discussion and Conclusion

In an effort to improve assay performance against emerging SARS-CoV-2 variants the *PLUS* Combination Test introduces an additional SARS-CoV-2 target (RdRp), as this region has is unmodified in all circulating variants of concern (te Velthuis *et al.*, 2009; Pachetti *et al.*, 2020; Peng *et al.*, 2020), and has introduced redesigned N2 oligos for better coverage of circulating

mutations that caused N gene target dropout (Foster et al., 2022; Isabel et al., 2022). Here, we 168 169 investigated the performance characteristics of the *PLUS* Combination Test comparing it to the 170 SARS-CoV-2/Flu/RSV combination test authorized for use in Canada since January, 2021. This study used a total of 160 clinical samples (including mixtures) that were processed at two 171 independent institutions, of which 110 samples were positive for SARS-CoV-2, influenza A, 172 173 influenza B, RSVA, and/or RSVB. There was no observable difference in assay run time, 174 sensitivity, specificity, or reported Ct value between the PLUS Combination Test and SARS-175 CoV-2/Flu/RSV combination test – with the possible exception of a slight decrease in RSVA Ct 176 value with the *PLUS* Combination Test across a small number of samples. Overall, the results 177 between the two assays were nearly identical for all targets, with agreement approaching 100%. 178 The only discordant sample between the two assays was a high-Ct (32.3) Influenza B sample 179 detected only with the SARS-CoV-2/Flu/RSV Combination Test. This likely reflects detection 180 variability due to the low concentration of the target near its LOD, rather than a difference in 181 performance between the two assays.

This observation was consistent for all variants tested. These results demonstrate that the Ct value for RdRp detection of SARS CoV-2 likely falls at or above the E and N2 targets producing little to no change to the reported Ct value. In conclusion, as the performance characteristics of the tests are nearly identical, the *PLUS* Combination Test can effectively replace the SARS-CoV-2/Flu/RSV combination test.

187 References

Becker, M. G. *et al.* (2020) 'Recommendations for sample pooling on the Cepheid GeneXpert[®] system using the
Cepheid Xpert[®] Xpress SARS-CoV-2 assay', *PLOS ONE*. Edited by J.-L. E. Darlix. Public Library of Science, 15(11), p.
e0241959. doi: 10.1371/journal.pone.0241959.

Berry, L. *et al.* (2020) 'Point of care testing of Influenza A/B and RSV in an adult respiratory assessment unit is
 associated with improvement in isolation practices and reduction in hospital length of stay', *Journal of Medical*

- 193 *Microbiology*, 69(5), pp. 697–704. doi: 10.1099/jmm.0.001187.
- Broder, K. *et al.* (2020) 'Test agreement between roche cobas 6800 and cepheid genexpert xpress sars-cov-2 assays
 at high cycle threshold ranges', *Journal of Clinical Microbiology*, 58(8). doi: 10.1128/JCM.01187-20.

Cepheid Package Insert (2021) 'Xpert [®] Xpress SARS-CoV-2/Flu/RSV Instructions For Use with GeneXpert Dx or
 GeneXpert Infinity Systems'. Cepheid, 302–5707(Rev. A).

- Foster, C. S. *et al.* (2022) 'SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay
 instability', *Pathology*, 54(4): 499–501.
- 200 Goldenberger, D. et al. (2020) 'Brief validation of the novel GeneXpert Xpress SARS-CoV-2 PCR assay', Journal of

- 201 *Virological Methods*, 284(July), pp. 8–10. doi: 10.1016/j.jviromet.2020.113925.
- 202 Gotham, D. et al. (2021) 'Public investments in the development of GeneXpert molecular diagnostic technology',
- 203 PLoS ONE, 16(8 August). doi: 10.1371/journal.pone.0256883.
- Hogan, C. A. *et al.* (2020) 'Five-minute point-of-care testing for SARS-CoV-2: Not there yet', *Journal of Clinical Virology*. Elsevier B.V., 128. doi: 10.1016/J.JCV.2020.104410.
- Isabel, S. *et al.* (2022) 'Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR
 detection in Canada', *Scientific Reports*, *12*(1), 1-7.
- Johnson, G. *et al.* (2021) 'Clinical evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV combination
 test', *Journal of Clinical Virology Plus*, 1(1), pp. 100014. doi: 10.1016/j.jcvp.2021.100014.
- 210 Johnson, G. et al. (2022) ' Clinical Evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV PLUS
- 211
 Combination Test', medRxiv. Cold Spring Harbour Laboratory Press, p. 2022.11.07.22281957. doi:

 212
 https://doi.org/10.1101/2022.11.07.22281957
- Jokela, P. *et al.* (2020) 'SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency department: evaluation and utility', *Journal of Clinical Virology*. Elsevier B.V., 131. doi: 10.1016/J.JCV.2020.104614.
- Lieberman, J. et al. (2020) 'Comparison of Commercially Available and Laboratory Developed Assays for in vitro
- 216 Detection of SARS-CoV-2 in Clinical Laboratories', *medRxiv*. Cold Spring Harbor Laboratory Press, p.
- 217 2020.04.24.20074559. doi: 10.1101/2020.04.24.20074559.
- 218 Moran, A. *et al.* (2020) 'The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas
- SARS-CoV-2 Assays', *Journal of Clinical Microbiology*. American Society for Microbiology Journals. doi:
 10.1128/JCM.00772-20.
- Pachetti, M. *et al.* (2020) 'Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA
 polymerase variant', *J Transl Med*, 18, p. 179. doi: 10.1186/s12967-020-02344-6.
- Peng, Q. *et al.* (2020) 'Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2', *Cell Reports*, 31(11). doi: 10.1016/j.celrep.2020.107774.
- Rakotosamimanana, N. *et al.* (2020) 'GeneXpert for the diagnosis of COVID-19 in LMICs', *The Lancet Global Health*.
 Elsevier Ltd, 8(12), pp. e1457–e1458. doi: 10.1016/S2214-109X(20)30428-9.
- 227 Respiratory Virus Infections Working Group (2020) 'Canadian Public Health Laboratory Network: Prioritized
- support for northern, remote and isolated communities in Canada', *Can Commun Dis Rep*, 46(10), pp. 322–323.
 doi: 10.14745/ccdr.v46i10a02.
- Rong, K. et al. (2022) 'Validation of the Cepheid Xpert® Xpress SARS-CoV-2 using upper and lower respiratory tract
- specimens', European Journal of Microbiology and Immunology. Akadémiai Kiadó, 12(1), pp. 18–21. doi:
 10.1556/1886.2022.00003.
- Smithgall, M. C. *et al.* (2020) 'Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid
 Detection of SARS-CoV-2', *bioRxiv*. Cold Spring Harbor Laboratory, p. 2020.04.22.055327. doi:
- 235 10.1101/2020.04.22.055327.
- Tham, J. W. M. et al. (2021) 'Parallel testing of 241 clinical nasopharyngeal swabs for the detection of SARS-CoV-2
- virus on the Cepheid Xpert Xpress SARS-CoV-2 and the Roche cobas SARS-CoV-2 assays', *Clinical Chemistry and*
- 238 Laboratory Medicine. De Gruyter Open Ltd, 59(2), pp. E45–E48. doi: 10.1515/CCLM-2020-
- 239 1338/MACHINEREADABLECITATION/RIS.
- te Velthuis, A. J. W. *et al.* (2009) 'The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent',
 Nucleic Acids Research, 38(1), pp. 203–214. doi: 10.1093/nar/gkp904.
- 242 Wolters, F. et al. (2020) 'Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the
- 243 SARS-CoV-2 pandemic', *Journal of Clinical Virology*. Elsevier, 128(May 2020), p. 104426. doi:
- 244 10.1016/j.jcv.2020.104426.

- 245 World Health Organization (2020) 'Rapid communication on the role of the GeneXpert[®] platform for rapid
- 246 molecular testing for SARS-CoV-2 in the WHO European Region European Laboratory Initiative on TB, HIV and Viral
- 247 Hepatitis: 1 April 2020', (April). Available at: https://apps.who.int/iris/handle/10665/336322 (Accessed: 9
- 248 September 2022).
- 249 Yau, F. et al. (2021) 'Clinical utility of a rapid "on-demand" laboratory-based SARS-CoV-2 diagnostic testing service
- in an acute hospital setting admitting COVID-19 patients', *Clinical Infection in Practice*. Elsevier B.V., 12. doi:
- 251 10.1016/J.CLINPR.2021.100086.
- Zhen, W. et al. (2020) 'Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2',
- 253 Journal of Clinical Microbiology. American Society for Microbiology Journals. doi: 10.1128/JCM.00783-20.
- 254
- 255
- 256 The authors have no competing interests to disclose.
- All primary research data used to generate this manuscript are included in-text and within Supplementary file 1.

Table 1: Detection of five SARS-CoV-2 Variants. Materials tested were cultured SARS-CoV-2, inactivated by gamma-irradiation. SARS-CoV-2 concentrations were adjusted to target Ct values of 33 and 36, followed by testing with the Xpert SARS-CoV-2/Flu/RSV Combination Test or Xpert SARS-CoV-2/Flu/RSV *PLUS* Combination Test. Each dilution was tested in duplicate (indicated as Replicate 1 [Rep1] and Replicate 2 [Rep2] below).

	SARS-CoV-2 Variant	SARS-CoV-2 /Flu/RSV		SARS-CoV-2 /Flu/RSV <i>PLUS</i>	
	(mactivated culture)	Rep1	Rep2	Rep1	Rep2
Ct = 33	Wild Type WA-1	30.2	32.2	32.9	32.8
	Alpha B.1.1.7	32.2	32.1	33.4	33.2
	Delta B.1.617.2	33.7	33.8	34.2	34.8
	Omicron BA.1.1	33.7	32.3	33.2	32.7
	Omicron BA.2	33.7	33.4	33.0	32.4
Ct = 36	Wild Type WA-1	35.8	35.5	36.1	36.0
	Alpha B.1.1.7	35.4	35.7	35.6	36.1
	Delta B.1.617.2	36.4	36.4	37.3	37.5
	Omicron BA.1.1	36.4	37.1	35.8	35.9
	Omicron BA.2	36.2	37.6	36.0	35.3

Note: Ct: Cycle threshold

Table 2: Concordance of the Xpert SARS-CoV-2/Flu/RSV Combination Test with the XpertSARS-CoV-2/Flu/RSV PLUS Combination Test forthe detection of SARS-CoV-2.

Result with	Result with Xpert SARS-CoV- 2/Flu/RSV <i>PLUS</i>			
Xpert SARS-	SARS-CoV-2			
CoV-2/Flu/RSV	Positive	Negative		
Positive	57	0		
Negative	0	103		

Table 3: Concordance of the Xpert SARS-CoV-2/Flu/RSV Combination Test with the SARS-CoV-2/Flu/RSV *PLUS* Combination Test for the detection of Influenza A, Influenza B and RSV.

Result with	Result with Xpert SARS-CoV-2/Flu/RSV PLUS						
Xpert SARS-	Influenza A		Influenza B		RSVA/B		
Cov-2/Flu/RSV	Positive	Negative	Posit ive	Negative	Positive	Negative	
Positive	21	0	19	1	25	0	
Negative	0	139	0	140	0	135	



Figure 1: Ct value comparisons between the Xpert SARS-CoV-2/Flu/RSV Combination Test and SARS-CoV-2/Flu/RSV *PLUS* Combination Test. Results shown for: A) SARS-CoV-2; B) Respiratory Syncytial Virus; C) Influenza A; and D) Influenza B. Correlation (R²) is calculated for each target.